Daily Newsletter

20 November 2023

Daily Newsletter

20 November 2023

Australia selects provider for Morphett Vale Medicare UCC

The clinic will operate extended hours seven days a week, providing walk-in care that is fully bulk billed.

November 17 2023

The Australian Government has finalised the provider for the Morphett Vale Medicare Urgent Care Clinic (UCC) in South Australia.

The Morphett Vale Family Practice will operate as the UCC and begin serving patients in December.

This initiative is said to be part of the government's commitment to making urgent medical treatment more accessible to South Australians.

The clinic will operate extended hours seven days a week, providing walk-in care that is fully bulk billed.

This facility is expected to alleviate pressure on Noarlunga Hospital by addressing non-urgent or semi-urgent care needs at the clinic.

Morphett Vale Medicare UCC is one of five planned clinics for South Australia.

Similar facilities are now operational in Elizabeth and Marion, and clinics in western Adelaide, Mount Gambier, and Morphett Vale will open before the end of the year.

The government will collaborate with Primary Health Networks and the Malinauskas Government to implement these Medicare UCCs.

Minister Picton said: “The Morphett Vale Medicare UCC will help to ease pressure of lower priority cases on local emergency departments and be much more convenient for southern suburbs residents.

“I know that many residents will welcome this alternative to attending an emergency department.

“Locals will be able to walk in, see a doctor or nurse, and access imaging and pathology services. All of these services will be bulk-billed and come at no additional cost to patients.

"We welcome this investment from the Federal Government into both urgent care centres and increasing bulk billing rates, addressing the lack of primary care that has led to pressure on hospitals like Noarlunga.”

Is it time for the healthcare sector to fully embrace the benefits of digitalization and AI?

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close